# Adiponectin in Patients With Metabolic Disorders

> **NCT07539584** · NA · COMPLETED · sponsor: **Moscow Regional Research and Clinical Institute (MONIKI)** · enrollment: 130 (actual)

## Conditions studied

- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** SGLT2 inhibitor
- **DRUG:** GLP-1 RA

## Key facts

- **NCT ID:** NCT07539584
- **Lead sponsor:** Moscow Regional Research and Clinical Institute (MONIKI)
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-01
- **Primary completion:** 2024-04-08
- **Final completion:** 2024-04-08
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07539584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07539584, "Adiponectin in Patients With Metabolic Disorders". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07539584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*